Search Results

You are looking at 101 - 110 of 866 items for :

  • Refine by Access: All x
Clear All
Full access

Hodgkin Lymphoma, Version 2.2015

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Hema Sundar

treatment and no treatment-related deaths or secondary leukemia were reported. Among 16 patients who experienced disease relapse, the freedom from second relapse was 69% at 5 years. Other investigators have also confirmed that the Stanford V regimen is

Full access

Updates to the Management of Multiple Myeloma

Presented by: Natalie S. Callander and Shaji K. Kumar

need to transplant, but whether it is better as part of up-front treatment or at the time of relapse.” Other questions regarding the optimal strategy were addressed by the FORTE trial. In this study, among several approaches, outcomes were best in

Full access

Management of Advanced Germ Cell Cancer in Patients With Unfavorable Prognosis

Kim Margolin

. J Clin Oncol 1996 ; 14 : 2631 – 2637 . 8 Margolin KA Doroshow JH Frankel P . Taxol-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer . (Submitted for publication) . 9 Broun ER

Full access

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes

decreased in older patients treated with PCI compared with younger patients regardless of stage. 149 Surveillance for Relapse Although SCLC is very responsive to initial treatment, most patients relapse with relatively resistant disease (see also

Full access

Use of PARP Inhibitors for Ovarian Cancer

Presented by: Deborah K. Armstrong

there is no information on whether these benefits would be seen in patients who had previously received PARP inhibitors. Recurrent Disease Active treatment of relapsed disease with PARP inhibitors has also been well tested in BRCA -positive

Full access

Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme

Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick

locally, with 90% of relapses occurring within 2 cm of the original tumor. 4 As reflected in the NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, therapies are variable and depend on the extent of recurrence and the

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

criteria for a CR or PR are considered to have stable disease. Relapse is defined as evidence of disease progression 6 months or more after an initial CR or PR. Refractory disease is defined as failure to experience a response or experiencing disease

Full access

Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar

cancer. BMC Cancer 2006;6:194; and Elkum N, Dermime S, Ajarim D, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007;7:222. Based on international

Full access

Postconsolidation Maintenance and Monitoring in Patients With Acute Promyelocytic Leukemia

Chezi Ganzel, Dan Douer, and Martin S. Tallman

Era ATO is considered the most potent anti-APL agent. Its use, which was traditionally reserved for patients experiencing relapse, has expanded and become more a part of induction-consolidation therapy. 15 , 16 Recently, primary results of the APL

Full access

Management of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia

Samuel J. Slomowitz and Paul J. Shami

, chloroma , or myeloblastoma ), leukemia cutis (LC), and central nervous system (CNS) disease. Extramedullary disease at presentation or relapse can pose unique clinical problems. In general, the basic principles of systemic therapy remain the same. The